Advertisement

Cytochrome P450 in Human Drug Metabolism: How Much Is Predictable?

  • U. A. Meyer
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 13)

Abstract

Cytochrome P450 (CYP) mono-oxygenases represent one of the major enzyme systems that determine the organism’s capability of dealing with drugs and chemicals. Studies over the past 20 years have provided evidence that cytochromes P450 occur in many different forms (isoforms or isozymes) which differ in spectral, chemical, and immunological properties and have different substrate affinities. These isozymes also differ in their regulation and tissue distribution. Recombinant DNA studies indicate that between 50 and 200 structural genes may code for different cytochrome P450 isozymes in a single organism. Close to 30 human cytochrome P450 genes have now been characterized. The multiplicity of P450 isozymes explains in part the literally thousands of substrates known to be metabolized by this system (for review, see Nelson et al. 1993).

Keywords

Poor Metabolizers Human Cytochrome CYP2D6 Gene Cytochrome P450 Isozyme CYP2D6 Allele 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Meyer UA, Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36: 521–530PubMedCrossRefGoogle Scholar
  2. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA (1989) Lidocaine metabolism in human liver by cytochrome P450IIIA4 (PCN1). Clin Pharmacol Ther 46: 521–527PubMedCrossRefGoogle Scholar
  3. Broly F, Gaedigk A, Heim M, Eichelbaum M, Mörike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10: 545–558PubMedCrossRefGoogle Scholar
  4. Daly AK, Cholerton S, Gregory W, Idle JR (1993) Metabolic polymorphisms. Pharmacol Ther 57: 129–160PubMedCrossRefGoogle Scholar
  5. DeMorais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for thepolymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15422–15422Google Scholar
  6. Fonné-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P450db1 function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37: 3829–3835PubMedCrossRefGoogle Scholar
  7. Gascon MP, Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41: 573–578PubMedCrossRefGoogle Scholar
  8. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYPC19 is the major s-mephenytoin 4’hydroxylase in humans. Biochemistry (in press)Google Scholar
  9. Gonzalez FJ (1992) Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 13: 346–352PubMedCrossRefGoogle Scholar
  10. Guengerich FP, Müller-Enoch D, Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30: 287–295PubMedGoogle Scholar
  11. Heim M, Meyer UA (1990) Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529–532PubMedCrossRefGoogle Scholar
  12. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjoeqvist F, IngelmanSundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90: 11825–11829PubMedCrossRefGoogle Scholar
  13. Kalow W (1992) Pharmacogenetics of drug metabolism international encyclopedia of pharmacology and therapeutics (executive editor AC Sartorelli). Pergamon, LondonGoogle Scholar
  14. Kalow W, Goedde HW, Agarwal DP (1986) Ethnic differences in reactions to drugs and xenobiotics. Liss, New YorkGoogle Scholar
  15. Kronbach T, Fischer V, Meyer UA (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P450 of the P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630–635PubMedCrossRefGoogle Scholar
  16. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36: 89–96PubMedGoogle Scholar
  17. Meier PJ, Mueller HK, Dick B, Meyer UA (1983) Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85: 682–692PubMedGoogle Scholar
  18. Meyer UA (1994) Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci USA 91 (in press)Google Scholar
  19. Meyer UA, Zanger UM, Grant D, Blum M (1990) Genetic polymorphisms of drug metabolism. In: Testa B (ed) Advances in drug research, vol 19. Academic, London, pp 307–23Google Scholar
  20. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW (1993) the P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12: 1–51Google Scholar
  21. Okey AB (1990) Enzyme induction in the cytochrome P450 system. Pharmacol Ther 45: 241–298PubMedCrossRefGoogle Scholar
  22. Waxman DJ, Azaroff L (1992) Phenobarbital induction of cytochrome P450 gene expression. Biochem J 281: 577–592PubMedGoogle Scholar
  23. Whitlock JP (1993) Mechanistic aspects of dioxin action. Chem Res Toxicol 6: 754–763PubMedCrossRefGoogle Scholar
  24. Wilkinson GR, Guengerich FP, Branch RA (1992) Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W (ed) Pharmacogenetics of drug metabolism, vol 2. Pergamon, New York, 657–685Google Scholar
  25. Zanger UM, Vilbois F, Hardwick J, Meyer UA (1988) Absence of hepatic cytochrome P450buf1 causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447–5454PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • U. A. Meyer

There are no affiliations available

Personalised recommendations